DGAP-Adhoc: WINCOR NIXDORF Aktiengesellschaft: WINCOR

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 25, 2016 at 2:30 AM

DGAP-Adhoc: WINCOR NIXDORF Aktiengesellschaft:

WINCOR NIXDORF Aktiengesellschaft / Key word(s): Change in Forecast 24.01.2016 20:58 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Net sales up substantially and earnings boosted in first quarter - positive impact from restructuring - earnings guidance upgraded Wincor Nixdorf AG saw net sales rise by 14% year on year in the first quarter of the current fiscal year 2015/2016, while operating profit (EBITA) before restructuring expenses increased by 78%. After restructuring expenses EBITA was up by 46%. In absolute terms, net sales generated by the Group totaled EUR727 million (previous year: EUR640 million). Operating profit reached EUR66 million before restructuring expenses and EUR54 million after expenses for restructuring (prior-year EBITA: EUR37 million). Thus, measures centered around business restructuring and realignment proved beneficial in particular to the company's earnings performance. Against this background, the company has upgraded its earnings guidance for the current fiscal year 2015/2016. As part of the revised outlook, operating profit before restructuring expenses is expected to lie within a range of EUR160 to 190 million (previous guidance: EUR150 million). The upgraded guidance on earnings has no impact on the outlook previously issued with regard to net sales, which points to slight growth in this area. The upgraded earnings guidance for fiscal 2015/2016 contains a positive earnings contribution from the restructuring program that is much more pronounced than originally anticipated (EUR60 to 80 million instead of EUR50 million). At the same time, the restructuring expenses originally budgeted are not likely to be utilized in full (EUR30 million instead of EUR40 million). What is more, expenses incurred in this area may possibly be more than offset by a number of activities currently underway as well as further one-off factors. In fact, Wincor Nixdorf currently anticipates a positive net effect ranging from EUR0 to 30 million. For instance, the sale of ownership interests in the Group's "AEVI" business with cashless and mobile payment systems has progressed well. In this context, Wincor Nixdorf plans to dispose of a non-controlling interest in AEVI. Given the strong interest already shown by investors, the company is confident that this sales transaction will be successfully concluded in the coming months. Furthermore, Wincor Nixdorf is discussing the possibility of a cooperation agreement for its business activities in China. At present, negotiations are underway with a Chinese partner regarding its majority-stake investment in a joint venture covering Wincor Nixdorf's business dealings in that country. The outlook issued by Wincor Nixdorf for fiscal 2015/2016 does not include one-off costs that will come into effect on conclusion of the business combination with Diebold. They are estimated to be around EUR50 million. 24.01.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: WINCOR NIXDORF Aktiengesellschaft Heinz-Nixdorf-Ring 1 33106 Paderborn Germany Phone: +49 (0)5251 693 30 Fax: E-mail: info@wincor-nixdorf.com Internet: www.wincor-nixdorf.com ISIN: DE000A0CAYB2 WKN: A0CAYB Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...